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Abstract
Background: Neuroglobin (Ngb), one of novel members of the globin superfamily, is expressed
predominantly in brain neurons, and appears to modulate hypoxic-ischemic insults. The
mechanisms underlying Ngb-mediated neuronal protection are still unclear. For it is one of the
candidate protective factors for ischemic stroke, we conducted a case-control study to clarify the
association of Ngb polymorphisms with ischemic stroke in the Southern Chinese Han population.
Methods: 355 cases and 158 controls were recruited. With brain imaging, cases were subdivided
into large-artery atherosclerosis (LVD) and small-vessel occlusion (SVD) stroke. PCR amplified all
the four exons of Ngb and flanking intron sequence for each exon. Genotyping for Ngb was
achieved by direct sequencing and mismatched PCR-RFLP. Polymorphisms were studied both
individually and as haplotypes in each group and subgroup which subdivided according to gender or
age.
Results: Two intronic polymorphisms 89+104 c>t and 322-110 (6a)>5a were identified. The allele
frequency of 89+104 t was decreased in stroke cases. The protective effect seems to be more
pronounced in subgroups of female patients and age > 60 years. Also, we have confirmed decreased
LDL-C level and reduced hypertension and hypercholesterolemia in 89+104 t allele carriers. In
contrast, the 322-110 (6a)>5a genotype distribution was similar between cases and controls.
However, the haplotype 89+104 c>t/322-110 (6a)>5a was related with LVD and SVD stroke. The
haplotype c-5a was more frequent in both LVD and SVD groups while t-6a was more frequent in
controls.
Conclusion: Ngb polymorphism 89+104 t had protective effects on LVD and SVD in the Southern
Chinese Han population. A "hitchhiking" effect was observed for the 89+104 t/322-110 (6a)
genotype combination especially for LVD.
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Background
Neuroglobin  (Ngb, LocusID: 58157; GenBank:
DQ008010) is a newly discovered globular heme protein
in the vertebrate brain that displays a high affinity for oxy-
gen like myoglobin (Mb) and hemoglobin (Hb) [1]. Ngb is
preferentially expressed in the neurons, as well as some
endocrine tissues [1,2]. The highest Ngb concentration has
been found in the retina, which is also the highest O2-con-
suming organ of the body [3].
Ngb is hypoxia-inducible in cultures of cerebral cortical
neurons [4] and some neuronal cell lines, such as PC12,
immortalized rat hippocampal neuron (HN33) [5,6] and
hybrid dorsal root ganglia neuroblastoma cell (ND15)
[7]. Prolonged or sustained hypoxia increased Ngb expres-
sion in vitro [5] or in vivo [8]. The increasing magnitudes
of Ngb mRNA levels, ranging from 150% to 500%, can be
explained by various experimental conditions or cell lines
[6,8,9]. For example, Ngb mRNA was time-dependently
upregulated during the first 8 h in a constant hypoxic
environment of 1% O2, while no significant upregulation
occured before 48 h in 3% O2 [6]. However, there were
contradictory data as to whether Ngb was upregulated
under hypoxic conditions in brain [10,11]. Several factors,
namely species, brain region, severity and duration of
hypoxia, and the pattern of hypoxic exposures, could have
accounted for such disparate findings [9]. Cerebral
ischemia is another stimulus to Ngb expression, although
findings vary depending on the model used and the exper-
iment designed [12]. Focal cerebral ischemia is clearly
associated with Ngb induction, especially in the penum-
bra [4]. Transient global forebrain ischemia increases Ngb
expression in the gerbil cerebral cortex and serum, but not
in the hippocampus [13].
Ngb appears to show the neuroprotective potential fol-
lowing hypoxic and ischemic insults [13-15]. In cultured
cortical neurons, antisense-mediated down-regulation of
Ngb decreases cell viability under hypoxia, whereas addi-
tional Ngb improves HN33 cells survival [4]. After trans-
fected with Ngb-expressing plasmid, human
neuroblastoma cells (SH-SY5Y) are resistant to oxidative
injury induced by H2O2 [16]. Intracellular delivery of Ngb
by human immunodeficiency virus-1 transactivator of
transcription (TAT) protein transduction domain fails to
rescue rat retinal ganglion (RGC-5) or SH-SY5Y cells from
combined oxygen and glucose deprivation [17], whereas
in another case, Ngb-TAT-treated cultured rat cortical neu-
rons shows reduced sensitivity to hypoxia [18]. Adminis-
tration of anti-sense oligodeoxynucleotides directed
against Ngb exacerbates experimental stroke in vivo, while
intracerebral administration of Ngb with an adeno-associ-
ated virus vector reduces the focal cerebral infarct size
indeed [15]. Furthermore, overexpression of Ngb  in a
transgenic mouse model reduces cerebral infarct size fol-
lowing middle cerebral artery occlusion (MCAO) [14,19].
However, the mechanisms underlying Ngb-mediated neu-
ronal protection during hypoxic/ischemic stress remain
largely unknown. It seems to us unlikely that Ngb is pri-
marily an O2 transporter, because of its fairly low average
tissue concentration (approximately micromolar) com-
pared with Mb (0.2 mM or so) in muscles [20]. Several
proposed mechanisms include Ngb acting as an oxygen
sensor and storage molecule [21,22], operating as a gua-
nine nucleotide dissociation inhibitor and then increas-
ing levels of free Gβγ [23], interacting with neuronal
membrane proteins including Na-K-ATPase [24] and flo-
tillin-1 [25], and even acting as an intracellular ROS (reac-
tive oxygen species)/RNS (reactive nitrogen species)
scavenger [20,26] via reduction reactions leading to ferric-
Ngb conversion to ferrous-Ngb by endogenous reducing
enzyme systems [27]. Ngb not only decreases oxidative
stress induced ROS/RNS overproduction and lipid perox-
idation [4,14,28], but also attenuates subsequent mito-
chondrial dysfunction, apoptosis, and cell death [30,29].
Its antioxidant properties were consistent with the protec-
tive role against oxidative stress-induced injury [31].
Recently met NGB (ferric-NGB) was found acting not only
as scavenger of reactive species, but also as a target of the
self-generated reactive species [32].
Whatever its function and mechanism is, it can be sum-
marized that the majority of studies agrees that Ngb is
beneficial for neuronal survival during hypoxic/ischemic
stress. Based on aforementioned considerations, we
hypothesize that Ngb may be one of the candidate genes
associated with ischemic stroke. Human Ngb, located on
chromosome 14q24, has a 3 intron/4 exon structure
[1,33]. The aim of this study is to investigate the associa-
tion between Ngb  polymorphisms or genotypes and
ischemic stroke in the Southern Chinese Han population,
which is the first allele association study on human Ngb
and stroke.
Methods
Subjects
Patients undergoing cranial computed tomography (CT)
and magnetic resonance imaging (MRI) and diagnosed as
ischemic stroke according to World Health Organization
(WHO) criteria were prospectively recruited between Sep-
tember 1, 2004 and February 28, 2007. Cases with a his-
tory of malignant disorders, infections, cardiovascular
diseases and peripheral vascular diseases, atrial fibrilla-
tion, cerebrovascular malformations, brain tumors and
traumatic cerebrovascular diseases were excluded. Accord-
ing to the clinical features and the results of diagnostic
workup, the following causes of stroke were diagnosed
based on TOAST criteria [34]: LVD stroke, SVD stroke, car-
dioembolic (CE) stroke, and stroke of other determined
or undetermined etiology. Only patients with LVD stroke
and SVD stroke were included for further analysis. Among
them, 221 patients had LVD stroke (160 males and 61BMC Medical Genetics 2008, 9:110 http://www.biomedcentral.com/1471-2350/9/110
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females) and the mean age at onset was 66.61 ± 10.47
years (range: 41–88 years), 134 patients had SVD stroke
(76 males and 58 females) and the mean age at onset was
66.96 ± 7.62 years (range: 51–84 years). 158 unrelated
age- and sex-matched controls (103 males and 55 females,
mean age: 65.08 ± 10.44 years, range: 48–83 years) free of
clinically detectable cardiovascular or cerebrovascular dis-
ease and positive family history of cerebrovascular disease
were recruited from persons undergoing annual medical
examination. All subjects came from the Southern Chi-
nese Han population. The study was approved by the local
ethics committee, and informed consent was obtained
from all participants. Demographic data were collected
from stroke patients and controls. Hypertension was
defined as repeatedly elevated blood pressure (mean of 3
measurements) exceeding 140/90 mmHg or the use of
antihypertensive drugs. Diabetes mellitus is characterized
by recurrent or persistent hyperglycemia, and is diagnosed
by demonstrating any one of the following three:(1) fast-
ing plasma glucose level at or above 126 mg/dL (7.0
mmol/L), (2) plasma glucose at or above 200 mg/dL
(11.1 mmol/L) two hours after a 75 g oral glucose load as
in a glucose tolerance test, (3) random plasma glucose at
or above 200 mg/dL (11.1 mmol/L). Cigarette smoking is
defined as having smoked at least 1 cigarette per day for 1
year or more, and former smokers whose smoke cessation
more than five years are not included. Alcohol consump-
tion is defined as drinking alcohol at least 12 times during
the last year. [35]
Genotyping
Genomic DNA was extracted from peripheral blood with
QIAamp DNA Blood Minikit (QIAGEN GmbH, Hilden,
Germany). Primers used for PCR are illustrated in addi-
tional file 1 (Suppl. Table 1. Primers of Ngb and condi-
tions of PCR). PCR amplified all the four exons of Ngb
and 95–303 base pairs of the flanking intron sequence for
each exon. DNA sequencing was performed with an ABI
Prism 3730 genetic analyzer (Applied Biosystems Inc.,
Foster City, Calif.) by using an ABI dye terminator cycle
sequencing kit (Fig. 1). The mismatched PCR-RFLP (prim-
ers were showed in Suppl. Table 1.) was used for screening
the detected polymorphisms. Ten microlitres of PCR
product were digested with the appropriate restriction
enzyme according to the manufacturer's recommenda-
tions (New England Biolabs, Beverly, MA, USA) and fol-
lowed by a 2.5% agarose gel electrophoresis (Fig. 2). The
Chromatograms of the polymorphisms 89+104 c>t and 322-110 (6a)>5a identified in the Ngb gene Figure 1
Chromatograms of the polymorphisms 89+104 c>t and 322-110 (6a)>5a identified in the Ngb gene. Normal 
sequences are shown in the upper of each box, and the corresponding polymorphisms are shown in middle and down of each 
box.BMC Medical Genetics 2008, 9:110 http://www.biomedcentral.com/1471-2350/9/110
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D2000 marker (Tianwei Inc, Beijing, China) ranging from
100 bp to 2000 bp was used as the size marker.
Statistical Analysis
Data on quantitative characteristics are expressed as
means ± SD. Data on qualitative characteristics are
expressed as percent values or absolute numbers, as indi-
cated. Differences in demographic characteristics and vas-
cular risk factors between patients and controls were
initially compared by univariate analysis using Student's t
test (for 2 groups) or ANOVA (for 3 groups) for continu-
ous variables and the χ2 test for all categorical variables.
Tests for Hardy-Weinberg equilibrium were conducted
using χ2 tests. Genotypes and allele frequencies were com-
pared by χ2 analysis or Fisher's exact test. Multivariate
logistic regression analysis was used to determine the
influence of Ngb polymorphisms on disease risk, control-
ling potential confounding risk variables including age,
sex, and other conventional risk factors. A forward step-
wise (Likelihood Ratio) procedure was used for multivar-
iable analysis. The associations of haplotypes comprising
Ngb polymorphisms with ischemic stroke were estimated
using SHEsis Software [36]. Data were analyzed with the
SPSS 13.0 package (SPSS Inc) and results were considered
statistically significant at P < 0.01 using a 2-tailed test. The
two intronic SNPs, 89+104 c>t (rs4903565) and 322-110
(6a)>5a (rs28909968) of Neuroglobin were identified.
Genotyping observations were performed blind by differ-
ent investigators. The post hoc power analysis was done
by PASS2005 software.
Results
Subject Characteristics
Demographic data and risk factor profiles of patients and
controls are presented in additional file 2 (Suppl. Table 2.
Clinical and biochemical characteristics of three groups).
Concerning the gender, BMI, alcohol intake and smoking,
there were no significant differences between cases and
controls. However, some risk factors did differ. For exam-
ple, hypertension and diabetes were more common than
controls in LVD, but only hypertension was more com-
mon in SVD patients. LDL-C, TC and TG levels were sig-
nificantly higher in LVD than in controls, while only LDL-
C level was higher in SVD. HDL-C level was lower in
stroke patients especially in LVD patients. Mean age and
gender composition did not differ between LVD or SVD
patients.
Association with Ngb Genotypes and Alleles
Two intronic SNPs, 89+104 c>t (rs4903565) and 322-110
(6a)>5a (rs28909968) of Neuroglobin, were identified in
this study (Fig. 1 and 3). Both polymorphisms were in
Hardy-Weinberg equilibrium for the total group and each
group separately. Among all the 513 subjects, genotyping
of 89+104 c>t for 120 LVD and 120 SVD patients was all
done by direct sequencing. The miamatched PCR-RFLP
was used for the remained 273 subjects. Genotypes and
allele frequency distributions are presented in Table 1. In
the control group, the frequencies of the cc, ct and tt gen-
otypes for 89+104 c>t were 0.146, 0.538, and 0.316,
respectively. The frequency of the tt genotype and the fre-
quency of t allele was significantly lower in the LVD and
SVD group than in the control group (P < 0.01). When the
sexes were analyzed separately, men with SVD did not
have significantly lower t allele frequency than those with-
out (P = 0.036); while men with LVD and women with
LVD or SVD had a significant lower t allele frequency (P <
0.01). After separated into >60 and ≤ 60 years subgroups,
the tendency to t allele frequency decreases can be
observed by comparing the control group to patients with
age >60 years (P < 0.01), although patients with age ≤ 60
years had a lower t allele frequency too, which was not sig-
nificant (P = 0.011 and 0.030 for LVD and SVD). Geno-
typing of 322-110 (6a)>5a was all done by direct
sequencing. The 322-110 (6a)>5a genotype distribution
was similar in patients with LVD or SVD stroke when com-
pared with controls, which may be due to lack of power
(power = 0.0794 and 0.2359 for LVD and SVD respec-
tively) or there is no association in fact.
Odds Ratios for associations between Ngb  polymor-
phisms and LVD or SVD phenotype were showed in Table
2, Table 3 and additional file 3 (Suppl. Table 3. Univariate
Mismatched PCR-RFLP analysis of the 89+104 c>t polymor- phism Figure 2
Mismatched PCR-RFLP analysis of the 89+104 c>t 
polymorphism. KpnI recognition site was created in the 
PCR product by means of mismatched primers KpnINgb. 
After cleavage with KpnI, the cc individuals (lane 5 and 6) car-
ried a 260 bp fragment, the tt individuals (lane 1 and 2) car-
ried a 284 bp fragment, and the ct individuals (lane 3 and 4) 
carried both 260 bp and 284 bp fragments. The size marker 
(M) is D2000 ranging from 100 bp to 2000 bp.BMC Medical Genetics 2008, 9:110 http://www.biomedcentral.com/1471-2350/9/110
Page 5 of 10
(page number not for citation purposes)
Table 1: Genotype and allele frequency distributions of Ngb polymorphisms
Ngb polymorphism All Male Female
Controls
n (%)
LVD
n (%)
SVD
n (%)
Controls
n (%)
LVD
n (%)
SVD
n (%)
Controls
n (%)
LVD
n (%)
SVD
n (%)
89+104 c>t
cc 23(14.6) 92(41.6) 52(38.8) 14(13.6) 67(41.9) 27(35.5) 9(16.4) 25(41.0) 25(43.1)
ct 85(53.8) 97(43.9) 56(41.8) 67(65.0) 66(41.3) 34(44.7) 18(32.7) 31(50.8) 22(37.9)
tt 50(31.6) 32(14.5) ** 26(19.4) ** 22(21.4) 27(16.8) ** 15(19.8)** 28(50.9) 5(8.2)** 11(19.0)**
c 131(41.5) 281(63.6) 160(59.7) 95(46.1) 200(62.5) 88(57.9) 36(32.7) 81(66.4) 72(62.1)
t 185(58.5) 161(36.4)** 108(40.3)** 111(53.9) 120(37.5)** 64(42.1)* 74(67.3) 41(33.6)** 44(37.9)**
H-W 0.173 0.437 0.128
322-110 (6a)>5a
6a6a 39(24.7) 53(24.0) 32(23.9) 25(24.3) 39(24.4) 18(23.7) 14(25.5) 14(23.0) 14(24.1)
6a5a 88(55.7) 118(53.4) 63(47.0) 58(56.3) 81(50.6) 38(50.0) 30(54.5) 37(60.7) 25(43.1)
5a5a 31(19.6) 50(22.6) 39(29.1) 20(19.4) 40(25.0) 20(26.3) 11(20.0) 10(16.4) 19(32.8)
6a 166(52.5) 224(50.7) 127(47.4) 108(52.4) 159(49.7) 74(48.7) 58(52.7) 65(53.3) 53(45.7)
5a 150(47.5) 218(49.3) 141(52.6) 98(47.6) 161(50.3) 78(51.3) 52(47.3) 57(46.7) 63(54.3)
H-W 0.142 0.312 0.508
Ngb polymorphism ≤ 60 years >60years
Controls
n (%)
LVD
n (%)
SVD
n (%)
Controls
n (%)
LVD
n (%)
SVD
n (%)
89+104 c>t
cc 13(18.8) 26(38.2) 15(41.7) 10(11.2) 66(43.1) 37(37.8)
ct 37(53.6) 32(47.1) 15(41.7) 48(53.9) 65(42.5) 41(41.8)
tt 19(27.5) 10(14.7)* 6(16.6)* 31(34.9) 22(14.4)** 20(20.4)**
c 63(45.7) 84(61.8) 45(62.5) 68(38.2) 197(64.4) 115(58.7)
t 75(54.3) 52(38.2)* 27(37.5)* 110(61.8) 109(35.6)** 81(41.3)**
322-110 (6a)>5a
6a6a 18(26.1) 16(23.5) 15(41.7) 21(23.6) 37(24.2) 17(17.3)
6a5a 36(52.2) 40(58.8) 14(38.9) 52(58.4) 78(51.0) 49(50.0)
5a5a 15(21.7) 12(17.6) 7(19.4) 16(18.0) 38(24.8) 32(32.7)
6a 72(52.2) 72(52.9) 44(61.1) 94(52.8) 152(49.7) 83(42.3)
5a 66(47.8) 64(47.1) 28(38.9) 84(47.2) 154(50.3) 113(57.7)
Compared with control group: *P < 0.05, **P < 0.01
H-W indicates Pearson's P value for χ2 test of Hardy-Weinberg equilibrium.
The positions of the two SNPs in the Ngb gene Figure 3
The positions of the two SNPs in the Ngb gene. '1 -89, 90 -201, 202 -321, 322 -456' show the positions of each exon in 
the human Ngb cDNA sequence. The intronic SNP positions in the human Ngb gene are indicated by arrows.BMC Medical Genetics 2008, 9:110 http://www.biomedcentral.com/1471-2350/9/110
Page 6 of 10
(page number not for citation purposes)
logistic regression analysis relatedto LVD and SVD). The
89+104 c>t was significantly associated with LVD patients
in multivariate analysis, including age, sex, TG, TC (HDL-
C and LDL-C), FIB, hypertension, diabetes mellitus type 2
and smoking. The event of LVD was significantly reduced
in tt compared with cc individuals (odds ratio of tt, 0.261;
95% CI, 0.130 to 0.527; P < 0.0001). Conversely, this
translated to an approximate 4-fold increased risk (odds
ratio, 3.825; 95% CI, 1.897 to 7.713; P < 0.0001) for cc
individuals relative to tt. However, 89+104 c>t was not
significantly associated with LVD patients in male sub-
group and ≤ 60 years subgroup. T allele of 89+104 c>t was
also associated with SVD stroke (odds ratio of t allele,
0.278; 95% CI, 0.156 to 0.495; P < 0.0001), especially in
female subgroup (odds ratio of t allele, 0.250; 95% CI,
0.102 to 0.612; P = 0.002). The LDL-C level of t allele car-
riers was lower than c/c homozygotes. In t allele carriers,
hypertension and hypercholesterolemia (Total Choles-
terol ≥ 240 mg/dl or 6.22 mmol/L) [37] were less com-
mon compared with c/c homozygotes.
Association with Ngb Haplotypes
Analysis of the two above genotypes resulted in 4 possible
haplotypes and the frequencies were given in Table 4. The
haplotype 89+104c/322-110(5a) (c-5a) was more fre-
quent in both LVD and SVD groups while the haplotype
89+104t/322-110(6a) (t-6a) was more frequent in con-
trols. The c-5a occurred in 33.7% of the LVD cases versus
21.7% of controls, yielding an odds ratio (OR) of 1.838
(95% CI, 1.318 to 2.563; P < 0.0001). And the effect of c-
5a on SVD risk was in the same direction as that observed
in LVD strokes (OR1.997, 95% CI, 1.384 to 2.880; P <
0.0001). Conversely, the t-6a occurred in 32.8% of con-
trols versus 20.8% of LVD and 23.3% of SVD, with the
ORs of 0.540 (95% CI, 0.389 to 0.750; P < 0.0001) and
0.623 (95% CI, 0.431 to 0.900; P = 0.011) respectively.
Discussion
For Ngb is hypoxia/ischemia-upregulated and shows the
neuroprotective potential during hypoxic/ischemic stress,
the Ngb polymorphisms may be one of the candidates for
being a genetic factor associated with ischemic stoke. In
the present study, we have investigated the association of
Ngb polymorphisms with ischemic stoke in the Southern
Chinese Han population.
It has been suggested that the pathogenesis in ischemic
stroke may be heterogeneous, differing between patients
with LVD stroke, SVD stroke or CE stroke. Therefore, the
studies of genetic factors for ischemic stroke should sub-
Table 2: Multivariate logistic regression analysis of Ngb polymorphisms related to LVD and SVD
LVD SVD
Odds Ratio (95%CI) * P* Odds Ratio (95%CI) * P*
89+104 c>t cc reference reference
ct 0.395 (0.219–0.711) 0.002 0.289(0.157–0.533) <0.0001
tt 0.261(0.130–0.527) <0.0001 0.256(0.127–0.515) <0.0001
c
t 0.351(0.199–0.617) <0.0001 0.278(0.156–0.495) <0.0001
322–110 (6a)>5a 6a6a reference reference
6a5a 1.164(0.665–2.037) 0.594 0.746(0.409–1.361) 0.340
5a5a 1.292(0.657–2.543) 0.458 1.336(0.662–2.697) 0.418
6a
5a 1.199(0.702–2.048) 0.506 0.894(0.505–1.582) 0.701
* Hypertension, DM 2, Smoking, TG level, HDL-C and LDL-C level have been adjusted.
Table 3: Multivariate logistic regression analysis of 89+104 c>t related to female and >60 years subgroups
89+104 c>t Female LVD vs control Female SVD vs control >60 years LVD vs control
Odds Ratio (95%CI)* P* Odds Ratio (95%CI)* P* Odds Ratio(95%CI) ** P**
cc reference reference reference
ct 0.634(0.231–1.740) 0.376 0.444(0.163–1.204) 0.111 0.242(0.104–0.563) 0.001
tt 0.062(0.017–0.230) <0.0001 0.128(0.044–0.371) <0.0001 0.219(0.086–0.556) 0.001
c reference reference reference
t 0.283(0.112–0.716) 0.008 0.250(0.102–0.612) 0.002 0.233(0.104–0.521) <0.0001
* Age, Hypertension, DM 2, Smoking, TG level, HDL-C and LDL-C level have been adjusted.
** Sex, Hypertension, DM 2, Smoking, TG level, HDL-C and LDL-C level have been adjusted.BMC Medical Genetics 2008, 9:110 http://www.biomedcentral.com/1471-2350/9/110
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divide according to the different clinical or etiological
subtypes to avoid false positive or negative results [38,39].
TOAST criteria were used to determine stroke etiology,
because they are thought to be the best available clinical
criteria to separate different stroke etiologies, although
they present an imperfect relationship to the underlying
inherited disease mechanism.
The cDNA sequence of Ngb  is highly conservative. No
mutations or polymorphisms within cDNA sequence
were found in subjects analyzed. However, two polymor-
phisms 89+104c>t and 322-110(6a)>5a were detected in
exon flanking sequence (95–303 bp). Other polymor-
phisms like rs28988618, rs101400032, rs7149300 and
rs10133981 were not identified in the present study.
According to the SNP on NCBI Reference Assembly, the t
carrier frequency of 89+104c>t was 50%, 21.4%, 66.7% in
European, African and Asian populations respectively
[40]. All the above data came from small sample ranged
from 14 to 46 subjects. The t carrier frequency of the con-
trol group in the present study was 58.5%. The 6a allele
frequency of 322-110 (6a)>5a was lower in the control
gruop of our study (52.5% vs 75%, 87.5% and 63% in
European, African and Asian populations) [41].
The significant differences in 89+104c>t genotype distri-
bution and allele frequency were found between LVD
patients or SVD patients and controls, which indicated
this polymorphism might be correlated with LVD and
SVD. T allele frequencies of LVD patients (36.4%) and
SVD patients (40.3%) were significantly lower than that
of the controls (58.5%). Conditional logistic regression
analysis showed that the presence of at least one t allele in
89+104c>t were probably potential independent protec-
tive factor, while hypertension was independent risk fac-
tors for both LVD and SVD stroke. DM2, TG and LDL-C
were independent risk factors for LVD stroke but not for
SVD stroke, while HDL-C was protective factor for LVD
stroke.
As we all known, confounding bias should conceal or
exaggerate the association between exposure factor and
the disease, thus resulted in the false negative or false pos-
itive. Age-bias and gender-bias are important considera-
tions in case-control study for cerebrovascular disease.
Data was analyzed by cluster stratification analysis to
exclude the interference of these confusion factors in this
study. T allele of 89+104c>t might be one of the inde-
pendent protect factors for LVD in females and people
over 60 years. The risk of LVD was further decreased in
female t allele carriers but not in males. Age stratified anal-
ysis suggested that t allele could reduce the LVD risk on
people over 60 years, but its protective effect on people
under 60 years was not significant. We also confirmed that
t allele might be a new protective factor for female SVD.
Since t allele was much more frequent in females than in
males, and t allele was significant protective especially for
females, we presumed that there should be some correla-
tions between Ngb protective effect and female hormones,
which remains to be confirmed by further studies.
The genotype distributions and allele frequencies of Ngb
322-110 (6a)>(5a) were similar between cases and con-
trols, which suggesting this site had no obvious correla-
tion with LVD or SVD. However, the haplotype 89+104c/
322-110(5a) showed a higher distribution frequency in
cases than in controls (OR = 1.838 for LVD, 1.997 for SVD
separately), indicating significant association with LVD
and SVD. Gradual increase of statistical power with the
inclusion of two polymorphisms supports the validity of
our conclusion that the Ngb is a susceptibility locus for
ischemic stroke.
Our data also showed that Ngb 89+104 t allele carriers
have a lower LDL-C level (P = 0.003), less frequent hyper-
cholesterolemia (P = 0.008) and hypertension (P <
0.0001) compared with c/c homozygotes. It is possible
that Ngb plays its role against ischemic injury related to
blood lipid metabolism or blood pressure regulation,
which probably find new way to investigation of Ngb pro-
tective mechanism. When the sex was analyzed separately,
Table 4: Association study with Ngb haplotypes in LVD and SVD patients
Haplotype Poly1/Poly2 LVD vs Control SVD vs Control
LVD
n (%)
Control
n (%)
OR (95%CI) P SVD
n (%)
Control
n (%)
OR (95%CI) P
c-6a 131.91(29.8) 62.48(19.8) 1.726(1.224–2.434) 0.002 64.59(24.1) 62.48(19.8) 1.288(0.869–1.910) 0.201
c-5a 149.09(33.7) 68.52(21.7) 1.838(1.318–2.563) <0.0001 95.42(35.6) 68.52(21.7) 1.997(1.384–2.880) <0.0001
t-6a 92.09(20.8) 103.53(32.8) 0.540(0.389–0.750) <0.0001 62.42(23.3) 103.53(32.8) 0.623(0.431–0.900) 0.011
t-5a 68.91(15.6) 81.47(25.8) 0.532(0.371–-0.762) 0.001 45.58(17.0) 81.47(25.8) 0.590(0.393–0.886) 0.010
Global χ2 36.407 20.966
Fisher P <0.0001 <0.0001
Poly1: 89+104 c>t; Poly2: 322-110 (6a)>5aBMC Medical Genetics 2008, 9:110 http://www.biomedcentral.com/1471-2350/9/110
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we found that the carrier of t allele have low LDL-C (P =
0.002), slightly high HDL-C level (P = 0.012) and low fre-
quent hypercholesterolemia (P = 0.003) and hyperten-
sion (P < 0.0001) in male subgroup. We concluded that
the 89+104c>t polymorphism show significant associa-
tion with plasma lipids level (LDL-C and HDL-C), hyper-
cholesterolemia and hypertension especially in Chinese
male.
As we all known, exonic polymorphisms have a potential
to change amino acid coding sequence. The current model
of pre-mRNA splicing is based on the recognition of four
canonical intronic motifs (5' splice site, branchpoint
sequence, polypyrimidine (PY) tract and 3' splice site),
however, it has become clear that the four canonical splice
elements do not contain adequate sequence information
to ensure accurate splicing. A few families of motifs that
are over-represented upstream of weak PY tracts were
identified and suggested as intronic splicing enhancers
(ISEs) that appear to compensate for a weakened canoni-
cal pre-mRNA splicing motif in both short and long
human introns [42-44]. Some intronic SNP, for example,
the intronic prothrombin 19911A>G is itself functional
and changes splicing efficiency by altering a known func-
tional pentamer motif CAGGG [45]. The intronic 89+104
c>t SNP could probably be assumed to influence the splic-
ing efficiency of Ngb by toggling between CCGGG and
CTGGG, which is one of the above motifs. Ngb's structure
shows a peculiar internal cavity of very large size. Binding
of heme ligands is associated to a conformational change
involving the heme that "slides" into the pre-existing cav-
ity and makes the sixth coordination position available
[46]. So the spatial conformation of Ngb is especial impor-
tant. We presumed that whether this intronic SNP influ-
enced nucleotide splicing and formed different
spliceosomes which might change the classical α helical
and three-over-three sandwich structure of Ngb, and then
resulted in the interference of protein folding, instead of
changing the amino acid coding sequence. Of course,
additional experimental evidence will need to be
obtained to verify the functional significance of the SNP
identified by our study.
Some potential biases may still have influenced our final
results. Prevalence of risk factors and stroke subtypes dif-
fer between hospitalized and community patients with
ischemic stroke. This case-control study was mainly hos-
pital-based, with comprehensive and accurate data, but
there would be inevitable selection bias compared with
community-based study. The lack of integrity data for
carotid ultrasound examination in controls may be
another weakness of this study, thus we have to reject
carotid internal media thickness data in our study.
Conclusion
In conclusion, t allele of 89+104c>t (rs4903565) might
have a protective effect against LVD and SVD in the South-
ern Chinese Han population, especially for female or peo-
ple over 60 years. Ngb  322-110(6a)>5a polymorphism
showed association with neither LVD nor SVD subtype.
However, there was a "hitchhiking" effect for ischemic
stroke was observed for the 89+104 t/322-110 (6a) geno-
type combination especially for LVD. To our knowledge,
this is the first study on correlation between Ngb polymor-
phisms and ischemic stroke has been investigated. These
results need to be further confirmed by some multicenter
case-control study or prospective study in different ethnic
populations.
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